Vincerx Pharma, Inc. Deferred Offering Costs
Vincerx Pharma, Inc. had Deferred Offering Costs of $2.30 million as of 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2020-11-10
- 2020-09-30: Deferred Offering Costs $2.30M.
- 2020-06-30: Deferred Offering Costs $2.30M.
- 2020-03-31: Deferred Offering Costs $2.30M.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-09-30 | $2.30M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $2.30M 10-K · filed 2020-09-23 |
| 2020-03-31 | $2.30M 10-Q · filed 2020-05-06 |